Thomas Ulmer

Chief Financial Officer

Managing Director Immatics Biotechnologies GmbH

Thomas Ulmer joined Immatics Biotechnologies GmbH in April 2018 from the Merck Group, where he was Chief Financial Officer of the Allergopharma Business Unit. During his tenure with Allergopharma he was the key architect for defining and implementing the business strategy towards geographic expansion and updating the product portfolio.

Thomas Ulmer began his professional career with Merck in 2004 and has held a number of roles, including Head of Business Planning & Analysis and previously Head of Planning, Forecasting & Resource Allocation for the Merck Group. During this time, he acted as a sparring partner to the Group Executive Board and helped develop and implement the new company strategy which included a major transformation. He has also been Chief Financial Officer for Australia/ New Zealand and Financial Controller for Merck’s global generics business when it was sold to Mylan and he played a leading role of the integration of the business and built up an OTC business unit in Australia for which he received the company’s innovation award.

Thomas Ulmer is a Certified Practising Accountant of CPA Australia and holds an MBA of Justus-Liebig-University of Giessen.

Back